Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 11, 2012, Pages 2069-2075

  Dallol, Ashraf ^a   Al Maghrabi, Jaudah ^a,b   Buhmeida, Abdelbaset ^a   Gari, Mamdooh A ^a   Chaudhary, Adeel G ^a   Schulten, Hans Juergen ^a   Abuzenadah, Adel M ^a   Al Ahwal, Mahmoud S ^a,b   Sibiany, Abdulrahman ^a,b   Al Qahtani, Mohammed H ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Aziz University   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYOD1 PROTEIN; PARAFFIN; POLYCOMB GROUP PROTEIN; PROTEIN MLH1; PROTEIN MSH2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 1; SLIT2 PROTEIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; COLON; COLORECTAL CANCER; DNA METHYLATION; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM; SAUDI ARABIA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; POLYCOMB-GROUP PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES; SAUDI ARABIA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84869239367     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0755     Document Type: Article

References (30)

1. Ferlay SHR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010 [cited 2011 October 1]. Available from: http://globocan.iarc.fr.
2. Al-Eid HS, Arteh SO. Cancer Incidence Report Saudi Arabia 1999-2000. Kingdom of Saudi Arabia: National Cancer Registry; 2004. Report No.: 6. Sponsored by the Ministry of Health.
3. Boyle T, Fritschi L, Heyworth J, Bull F. Long-term sedentary work and the risk of subsite-specific colorectal cancer. Am J Epidemiol 2011;173:1183-91.
4. Almurshed KS. Colorectal cancer: case-control study of sociodemographic, lifestyle and anthropometric parameters in Riyadh. East Mediterr Health J 2009;15:817-26.
5. Lao VV, Grady WM. Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol 2011;8:686-700.
6. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
7. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 2012;12:163-71.
8. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.
9. Purdie CA, Piris J, Bird CC, Wyllie AH. 17q allele loss is associated with lymph node metastasis in locally aggressive human colorectal cancer. J Pathol 1995;175:297-302.
10. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998;95:6870-5. (Pubitemid 28278073)
11. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev 2010;31:31-8.
12. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, et al. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. J Clin Oncol 2012;30:2256-64.
13. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res 2012;18:1506-12.
14. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008;3:e3698.
15. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006;125:301-13. (Pubitemid 44313811)
16. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Wesenberger DJ, Shen H, et al. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 2010;20:440-6.
17. Dunwell TL, Dickinson RE, Stankovic T, Dallol A, Weston V, Austen B, et al. Frequent epigenetic inactivation of the SLIT2 gene in chronic and acute lymphocytic leukemia. Epigenetics 2009;4:265-9.
18. Dallol A, Morton D, Maher ER, Latif F. SLIT2 axon guidance molecule is frequently inactivated in colorectal cancer and suppresses growth of colorectal carcinoma cells. Cancer Res 2003;63:1054-8. (Pubitemid 36278438)
19. Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A, et al. RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res 2011;31:2975-81.
20. Greene FL, Balch CM, Haller DG, Morrow M, editors. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 6th ed. Berlin: Springer; 2002.
21. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, et al. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 2011;31:4179-83.
22. Berg KD, Glaser CL, Thompson RE, Hamilton SR, Griffin CA, Eshleman JR. Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J Mol Diagn 2000;2:20-8.
23. Dallol A, Al-Ali W, Al-Shaibani A, Al-Mulla F. Analysis of DNA methylation in FFPE tissues using the MethyLight technology. Methods Mol Biol 2011;724:191-204.
24. Hawes SE, Stern JE, Feng Q, Wiens LW, Rasey JS, Lu H, et al. DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type. Lung Cancer 2010;69:172-9.
25. Houshdaran S, Cortessis VK, Siegmund K, Yang A, Laird PW, Sokol RZ. Widespread epigenetic abnormalities suggest a broad DNA methylation erasure defect in abnormal human sperm. PLoS ONE 2007;2:e1289.
26. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93. (Pubitemid 43980599)
27. Widschwendter M, Apostolidou S, Raum E, Rothenbacher D, Fiegl H, Menon U, et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS ONE 2008;3:e2656.
28. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci US A 1998;95:14863-8 (Pubitemid 29003722)
29. Arrieta O, Cardona AF, Federico Bramuglia G, Gallo A, Campos-Parra AD, Serrano S, et al. Genotyping non-small cell lung cancer (NSCLC) in Latin America. J Thorac Oncol 2011;6:1955-9.
30. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-30. (Pubitemid 44953403)